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AKT-mediated phosphorylation of TWIST1 is essential for breast cancer cell metastasis
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Abstract: Previously, it was shown that human TWIST1 (basic helix-loop-helix (b-HLH) is phosphorylated by Akt kinase at S42, T121,
and S123. To show in vivo effect of these phosphorylations, we created mouse TWIST1 expression vector and converted the codons
of S42, T125, and S127 to unphosphorylatable alanine and phosphorylation mimicking Glutamic acid. We hypothesized that alanine
mutants would inhibit the metastatic ability of 4T1 cells while glutamic acid mutants would convert nonmetastatic 67NR cells into
metastatic phenotype. To confirm this hypothesis, we created metastatic 4T1 and nonmetastatic 67NR cells expressing alanine mutants
and glutamic acid mutants mouse TWIST1, respectively. Then, we injected 1 × 106 67NR and 1 × 105 4T1 cells overexpressing mutants
of TWIST1 into the breast tissue of BALB/c mice. At the end of the 4th week, we sacrificed the animals, determined the numbers of
tumors at lungs and liver. Although 67NR cells overexpressing wild-type TWIST1 did not show any metastasis, cells overexpressing
S42E and T125E mutants showed 15–30 macroscopic metastasis to liver and lungs. Parallel to this, 4T1 cells expressing S42A and T125A
mutants of TWIST1 showed no macroscopic metastasis. Our results indicate that phosphorylation of S42 and T125 by AKT is essential
for TWIST1-mediated tumor growth and metastasis.
Key words: TWIST1, breast cancer, metastasis

1. Introduction
TWIST1 has been first characterized by its association
with the embryonic development of Saethre–Chotzen
syndrome and these individuals possess single
functional copy (haploinsufficiency) of TWIST1, and
this haploinsufficiency causes incomplete ossification
and skull development (Chen and Behringer, 1995;
Howard et al., 1997; el Ghouzzi et al., 1997; Qin et al.,
2012). Studies related to this have shown that TWIST1
inhibits ossification by inhibiting the activities of RUNX2
and MyoD1, which are responsible for osteogenic and
myogenic differentiation, respectively (Rice et al., 2000;
Bialek et al., 2004; Connerney et al., 2006). Recent
studies have shown that TWIST1 plays significant role
in tumorigenesis and in line with this, TWIST1 inhibits
apoptosis (Connerney et al., 2006), induces the expression
of oncogenes such as STAT3 (Yousfi et al., 2002), AKT2
(Gong and Li, 2002), p14ARF (Funato et al., 2001), and
accelerates p53 degradation (Xu et al., 2013). Parallel to
all these, TWIST1 expression is upregulated in many types
of cancer including glioma (Xu et al., 2017), stomach
(Mironchik et al., 2005), liver (Cheng et al., 2007),

endometrium (Cheng et al., 2008), breast (Xue et al., 2012),
prostate cancer (Elias et al., 2005), angiogenesis (Yan-Qi et
al., 2007), and epithelial-mesenchymal transition (Lee et
al., 2006). TWIST1 induces the expression of N-cadherin
while suppressing the expression of the epithelial marker,
E-cadherin (Lee et al., 2006; Kyo et al., 2006). As we were
conducting our studies to show the possible mechanism
of TWIST1 activation by AKT, Xue et al. (2012) showed
that TWIST1 is phosphorylated by AKT, and this
phosphorylation mediates cross-talk between PI3K/AKT
and TGF-B-signaling axes (Alexander et al., 2006).
TWIST1 protein has three AKT phosphorylation sites
in the consensus phosphorylation motif, RXRXXS/T.
These sequences in human are RKRRSS42, RERQRT121,
RQRTQS123, and in mouse are RKRRSS42, RERQRT125,
and RQRTQS127. From that time, AKT-mediated
phosphorylation of TWIST1 is already shown (Alexander
et al., 2006), we wanted to investigate the effect of our
mutants on growth, metastasis, and induction of TWIST1
induced Vimentin and N-cadherin in breast cancer cells
4T1 and 67NR cells as well. We found that nonmetastatic
67NR cells expressing glutamic acid mutants of TWIST1
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can, in fact, metastasize to both liver and lungs. In contrast,
metastatic 4T1 cells expressing alanine mutants of TWIST1
can no longer show any macroscopic metastasis to the liver
or lungs. Also, while alanine mutants of TWIST1 diminish
TWIST1-induced induction of N-cadherin and vimentin,
glutamic acid mutants significantly induced expression
of these genes in both cell types. Collectively, our results
clearly show that AKT-mediated phosphorylation of
TWIST1 is essential TWIST1-induced gene induction and
cancer cell metastasis.
2. Materials and methods
2.1. Construction of TWIST1 expression vector.
Mouse TWIST1 cDNA was cloned inframe into
pcDNA3.1A as BamHI fragment by using forward and
reverse primers shown below. Polymerase chain reaction
(PCR) protocol was applied with Taq DNA polymerase
(Fermentas). PCR: 1X reaction buffer, 2M MgCl2, 1 pmol
of each primer, 2µ Tag DNA polymerase, 100 ng DNA, and
5% DMSO. PCR conditions were: denaturation at 94 oC for
5 min, 35 cycles of steps at 94 oC for 45 s, 58 oC for 45 s, 72
o
C for 1 min, final extension was done at 72 oC for 7 min.
The PCR products and the pcDNA3.1A were digested
with BamHI and ligated with T4-DNA ligase at 16 oC
for 1 h, then the ligation products were transformed into
DH5a, plasmids were isolated from clones, and ligated
the insert orientation was confirmed via ApaI restriction
endonuclease digestion. Transfection of TWIST1
expression vector into 293 cells was performed using Caphosphate transfection protocol. Briefly, 30 ug of plasmid
DNA was resuspended in 1 mL of 2X HEPES buffer (pH:
7.05) and 1 mL of 0.25M CaCL2 was added dropwise
and the mixture was incubated at room temperature for
30 min, then CaCL2-DNA complex was added onto cells
dropwise. The transfected cells were incubated for 72 h,
the lysates were prepared for Western blotting.
Forward Pri.: 5’-cgcggatccgccaccatgatgcaggacgtgtccagc
tcgccagtctcgccgg-3’.
Reverse Pri: 5-cgcggatccgtgggacgcggacatggaccaggcccc-3,
Site Directed Mutagenesis: alanine (A) and glutamic
acid (E) mutations of TWIST1 were generated by
site directed mutagenesis (SDM) by using PFU DNA
polymerase (Fermentas). Mutagenesis primers used for
mouseTWIST1 are;
S42A; caagagacgcagcgcgcggcgcagcgcg, S42E; caagagacg
cagcgagcggcgcagcgcg,
T125A; agcgccagcgcgcccagtcgctg, T125E; ggagcgccagcg
cgagcagtcgctgaac,
S127A; cagcgcacgcaggcgctgaacgagg, S127E; ccagcgcacg
caggagctgaacgaggcg.
The generation of mutants was confirmed by DNA
sequencing using ABI-3130 (Figure S1).

2.2. Cell culture, cell lines, reagents, and antibodies
67NR and 4T1 cells were cultured in DMEM (Biochrom)
medium supplemented with 10% FBS (Biochrom) and 1%
(v/v) Pen-Strep Amp. solution (Biological Industries) in a
humidified 5% CO2 incubator at 37 oC. For the generation
of stable transfectants, cells were plated 24 h before
transfection and transfected with 30 ug plasmid DNA
using Ca-phosphate standard procedure. Stable clones
were selected with 800 μg/mL of neomycin/G418 (Roche)
for 8 weeks. Anti-Twist (sc-81417), anti-N-cadherin (sc59987) antivimentin (V9) (sc-6260) were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA).
2.3. Western blot
Protein concentrations of whole cell lysates obtained in
lysis buffer (20 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1.2% Triton X-100, 1 mM EGTA, 1 mM EDTA, 1 mM
PMSF, 0.15 U/mL aprotinin, 10 g/mL leupeptin, 10 g/
mL pepstatin A, and 1 mM sodium orthovanadate)
were determined using the Bradford method. Equal
amounts of protein were fractionated by SDS-PAGE on
10% polyacrylamide gels and transferred overnight to
Immobilon-P PVDF membranes (Millipore, Bedford,
MA, USA). The membrane was blocked with 1% BSA in
PBS-T buffer for 2 h at room temperature and probed
with anti-TWIST1 (Santa Cruz, Cat:#sc-81417) primary
antibody for 1 h at room temperature. After washing, the
membranes were incubated with peroxidase-conjugated
secondary antibody (Biorad, Cat No:# 1706516) for 1 h,
and proteins were detected using Clarity ECL western
blotting substrate (Bio-Rad, 1705061).
2.4. In vivo breast cancer model
Wild-type 4T1 and stable transfected 4T1 cells (105 cells
per mouse) were injected orthotopically into the right
upper mammary gland of 8–10-week-old BALB/c mice.
Identically wild-type 67NR and stable transfected 67NR
cells (106 cells per mouse) were injected into the mammary
pad of each mouse. Primary tumor, lung, and liver tissues
were removed 27 days after injection and fixed in 4%
formalin and embedded in paraffin.
2.5. Metastasis assay
Five serial sections (5 μm thick) were prepared from each
tumor sample. Slides were stained with hematoxylin and
eosin to determine metastasis lesions. Twenty pictures
were taken randomly with 20× magnification of each
mouse for metastasis assay. Metastatic lesions were
selected and measured as mm2 with Spot advanced 4.6
program (Diagnostic Instruments, Sterling Heights, MI).
2.6. Immunohistochemistry
Tissues were fixed in 4% formaldehyde (Merck;
#1040032500, NJ, USA) solution for 24 h and embedded in
paraffin. Sections of 5 μm were cut and collected on positive
charged slides (Thermo Fisher; #9951plus, MA, USA) and
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incubated overnight at 56 °C. Tissues were deparaffinized
in xylene (Merck; #1086852500, NJ, USA) and rehydrated
with ethanol (Merck; #1009832500, NJ, USA). Sections
were then treated with 10 mM citrate buffer, pH 6.0, for 5
min in a microwave oven. Following washes in phosphate
buffered saline (PBS), sections were incubated in a
universal blocking reagent (Scytek; #AAA125, UT, USA)
for 7 min at room temperature. Subsequently, sections
were incubated overnight at 4 °C with E-cadherin (1:50,
Santa Cruz; #sc8426, TX, USA), N-Cadherin (1:50, Santa
Cruz; #sc7939, TX, USA) and vimentin (1:50, Santa Cruz;
#sc373717, TX, USA) antibodies. After several washes
with PBS, sections were incubated with biotinylated goat
antirabbit (1:400; Vector Lab., #BA-1000, CA, USA) and
biotinylated horse antimouse (1:400; Vector Lab., #BA2000, CA, USA) secondary antibodies for 1 h at room
temperature and rinsed with PBS. Visualization was
provided via streptavidin-peroxidase complex (Scytek;
#SHP125, UT, USA) and diaminobenzidine (Sigma;
#D4186-50, MO, USA). Sections were counterstained
with Mayer’s hematoxylin (Merck; #1092490500, NJ, US)
and mounted with Kaisers Glycerin Gelatine (Merck;
#1079610100, NJ, US). Slides were examined using the
Zeiss-Axioplan microscope (Oberkochen, Germany).
3. Results
3.1. Cloning, mutagenesis, and expression of mouse
TWIST1
Mouse TWIST1 protein has 3 Akt phosphorylation sites at
S42, T125, S127 (Figure 1A). The gene has a single codingexon; we then amplified the exon with the cloning primers

and cloned as BamHI fragment into pcDNA3.1A, and
sequenced for sequence confirmation, and did not find
any change in the coding region. To determine whether
cloned cDNA express TWIST1 proteins, the expression
vector was transiently transfected into 293T cells for 48
h. Cellular lysates were prepared, 100 ug of lysates were
fractionated on 10% SDS-PAGE, and immunoblot was
labeled with anti-TWIST1 antibody. Since 293T cells
express almost undetectable level of TWIST1, we analyzed
relative expressions of our mutants with wild-type
TWIST1 to determine the fold expression. As shown in
Figure 1B, all TWIST1 mutants were expressed at a higher
level compared to wild-type TWIST1.
3.2. Phosphorylation of TWIST1 by AKT kinase is
essential for TWIST1-induced metastasis.
We have mouse breast cancer cell lines (4T1, 67NR), and
these cells share the same genetic background; however,
these cells show remarkably different metastatic potential
and express almost the same level of TWIST1. While 4T1
cells have very high metastatic ability to lung and liver,
67NR does not have metastatic features. According to
this information, we hypothesized that alanine mutants of
TWIST1 could not be phosphorylated at indicated sites,
and lack of phosphorylation would interfere with the
metastasis-inducing ability of TWIST1. Parallel to this,
the conversation of S42, T125, and S127 to glutamic acid
would create active TWIST1 and mimic the metastasisinducing capability of TWIST1. To demonstrate this
hypothesis, we stably transfected 4T1 with wild-type,
and alanine mutants and 67NR cells with wild-type and
glutamic acid mutants mouse TWIST1 and selected single

Figure 1. A) Amino acid sequence TWIST1 protein of mus musculus. AKT-phosphorylation sites (S42, T125, S127) are
in bold B) Subconfluent 4T1/67NR cells were cultured DMEM in 100 mm plates were transfected with 30 ug expression
vectors of alanine mutants and glutamic acid mutants of TWIST1 using calcium phosphate (Kingston et al. 2003) protocol
for 72 h. Cellular lysates were collected in lysis buffer, and 100 ug total protein lysates were fractionated on %10 SDSPAGE and blot was labeled with anti-TWIST1 antibody. The blot was stripped off and relabeled with anti-b-actin. Band
intensities were determined using Image J, and relative abundance of TWIST1 level was determined by dividing TWIST1
band intensities to that of b-Actin.
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clones for 8 weeks. Later, we injected 1 × 106 67NR and 1
× 105 4T1 cells overexpressing wild-type and mutants of
TWIST1 into the breast tissue of female inbred BALB/c
mice. We monitored animals for tumor growth and
metastasis, at the end of the 4th week, the animals were
sacrificed, lungs and livers were removed and the number
of tumors larger than 1 mm was determined. As shown
in Figures 2A and 2B, as expected, 4T1 cells metastasized
to lung and liver with a very high number, but contrary to
our expectation, ectopic expression of wild-type TWIST1
not only potentiated this, it also prevented metastasis.
However, alanine mutants behaved like TWIST1 and
significantly lowered lung metastasis and completely
eradicated metastasis to the liver. Although the results of
the ectopic expression of wild-type TWIST1 in 4T1 cells
was a great surprise to us, ectopic expressions of glutamic
acid mutants yielded expected results. As shown in Figures
3A and 3B, 67NR cells did not show any metastasis to lung
or liver, and similar to what we observed in 4T1 cells,
wild-type TWIST1 did not further induce metastasis to
liver and slightly induced metastasis to lung. However,
ectopic expressions of S42E and T125E mutants converted
nonmetastatic 67NR to metastatic cells and caused
significant metastasis to both lung and liver.
3.3. Alanine mutants of TWIST1 suppress the expression
of N-cadherin and vimentin in 4T1 cells.
Since we hypothesized that Akt-mediated phosphorylations
of TWIST1 would affect EMT in mouse breast cancer cell
lines, and alanine mutants of TWIST1 interfered with
metastasis of 4T1 cells we wanted to know whether ectopic

expression of alanine mutants affected the expressions
of N-cadherin and vimentin. Immunohistochemical
staining of tumors formed by 4T1 cells overexpressing
alanine mutants showed that 4T1 cells express a significant
amount of vimentin, and this was further increased by
wild-type TWIST1. However, the expression of vimentin
was significantly suppressed in 4T1 cells expressing
alanine mutants. We saw almost the same trend in the
suppression of N-cadherin expression by alanine mutants.
However, TWIST1 did not further increase the expression
of N-cadherin compared to 4T1 cells alone (figure 4).
3.4. Glutamic acid mutants of TWIST1 differentially
affect the expression of N-cadherin and vimentin in
67NR cells
Since there is a strong correlation between increased
TWIST1 expression and EMT, and ectopic expression
of S42E and T125E mutants of TWIST1 transformed
nonmetastatic 67NR cells into metastatic cells, we wanted
to explain the reason behind these observations. To do
that, we determined the level of expression of vimentin
and N-cadherin in tumor samples of 67NR cells. As
shown in Figure 5, in 67NR tumors, there is a detectable
level of N-cadherin and vimentin expression, and ectopic
expression of wild-type TWIST1 did not significantly
induce expressions of neither N-cadherin nor vimentin.
In fact, contrary to our expectations, ectopic expression of
wild-type TWIST1 and S42E mutants significantly lowered
the expression of N-cadherin, T125E showed almost
no effect. However, ectopic expression of S127E mutant
induced three-fold induction of N-cadherin compared to

Figure 2. Alanine mutants of TWIST1 suppresses lung (A) and liver (B) metastasis of 4T1 cells. The representative
graph shows the average number of macrometastasis in the lungs and liver. (Samples were compared with TWIST1
(WT) group for analyzing, *: P < 0.05)
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Figure 3. Glutamic acid mutants of TWIST1 convert nonmetastatic 67NR cells into metastatic cells. The representative
graph shows the average number of macro metastasis in the lungs and liver. (Samples were compared with TWIST1
(WT) group for analyzing, ****: P < 0.0001)

Figure 4. The effect of alanine mutants of TWIST1 mutants on N-cadherin and vimentin expression in 4T1 cells.
4T1 cells transfected with wild-type and alanine mutants of TWIST1 using Ca-phosphate standard procedure. Stable
clones were selected with 800 μg/mL of neomycin/G418 for 8 weeks. 1 × 105 4T1 cells expressing wild-type and
glutamic acid mutants of TWIST1 were injected orthotopically into the right upper mammary gland of 8–10-weekold BALB/c mice. Primary tumors were removed 27 days after injection. After the fixation of the primary tumor in
4% formaldehyde and embedded in paraffin, 5 μm thick serial sections were collected. Sections were immunostained
with N-cadherin and vimentin antibody. Slides were examined using light microscopy, and analysis was done using
Image J and Graphpad Prism (20× magnification) (Samples were compared with TWIST1 (WT) group for analyzing,
****: P < 0.0001)
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Figure 5. The effect of glutamic acid mutants of TWIST1 mutants on N-cadherin and vimentin expression in
67NR cells. 67NR cells transfected with wild-type and glutamic acid mutants of TWIST1 using Ca-phosphate
standard procedure. Stable clones were selected with 800 μg/mL of neomycin/G418 for 8 weeks. 1 × 106 67NR
cells expressing wild-type and glutamic acid mutants of TWIST1 were injected orthotopically into the right upper
mammary gland of 8–10-week-old BALB/c mice. Primary tumors were removed 27 days after injection. After
the fixation of the primary tumor in 4% formaldehyde and embedded in paraffin, 5 μm thick serial sections were
collected. Sections were immunostained with N-cadherin and vimentin antibody. Slides were examined using
light microscopy, and analysis was done using Image J and Graphpad Prism. (20× magnification) (Samples were
compared with TWIST1 (WT) group for analyzing, ****: P < 0.0001)

67NR and slightly induced vimentin expressions, although
it did not induce metastasis.
4. Discussion
TWIST1 is a transcription factor bearing bHLH DNAbinding domain and plays a pivotal role during embryonic
development, essential for the development of somite, limb
bud, and cranial neural tube in mammals. Heterozygous
loss-of-function mutation (LOH) of TWIST1 causes
Saethre–Chotzen syndrome both in mice and human
Alexander et al. 2006 (Chen et al., 1995; Howard et al.,
1997; el Ghouzzi et al., 1997; Rice et al., 2000; Bialek et
al., 2004; Connerney et al., 2006; Qin et al., 2012). Early
studies showed that the nonredundant role of TWIST1
during embryonic bone development was explained by
TWIST1-mediated inhibition of RUNX2 and MyoD1,
which are responsible for osteogenic and myogenic
differentiation, respectively (Funato et al., 2001; Yousfi et
al., 2002; Gong et al., 2002). Although TWIST1 is essential
during embryonic development, its expression is limited
to fibroblasts of the mammary glands (MGs) and dermal
papilla cells of the hair follicles (Xu et al., 2013).

Previous studies showed that TWIST1 is
overexpressed in the mammary glands, and its aberrant
expression was correlated with chromosomal instability,
in vivo angiogenesis, and metastasis of breast cancer cells
(Mironchik et al., 2005; Xu et al. 2017). Recently, it was
also shown that TWIST1 is phosphorylated by Akt, in
turn, TWIST1 transcriptionally upregulates AKT2 gene
in breast cancer cells, and this induction leads to invasion
and migration of breast cancer cells (Cheng et al., 2007;
Cheng et al., 2008; Xue et al., 2012). Although TWIST1
expression is limited to breast tissue and hair follicles in
healthy adult, recent findings showed that overexpression
and aberrant activation of TWIST1 has been linked to the
development of many cancers including but not limited
to gliomas, gastric cancer, hepatocellular carcinoma,
prostate cancer, endometrial cancer, colon cancer, and
bone cancer (Elias et al., 2005; Lee et al., 2006; Kyo et al.,
2006; Alexander et al., 2006; Yan-Qi et al., 2007; Singh,
2014; Wang et al., 2018).
In line with these, we wanted to contribute to the
significance of Akt-mediated phosphorylation of TWIST1
by using mouse breast cancer cell model. To directly
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test the impact of TWIST1 phosphorylation by Akt, we
genetically modified Akt phosphorylation sites (S42, T125,
S127) of TWIST1 using site-directed mutagenesis and
created glutamic acid and alanine mutants of indicated
sites. Since alanine mutants could not be phosphorylated,
we thought that the malignant mouse breast cancer cell
line (4T1) stably expressing alanine mutants of TWIST1
would lose metastatic ability when implanted into the
breast tissue of BALB/c mice. Indeed, as seen in Figure
2, the ectopic expression of alanine mutants almost
completely ablated metastasis of 4T1 cells to the liver and
severely diminished metastasis to the lungs. Parallel to
these, we thought that the nonmalignant mouse breast
cancer cell line (67NR) stably expressing glutamic acid
mutants of TWIST1 would gain metastatic ability when
implanted into the breast tissue of BALB/c mice. As
shown in Figure 3, S42E and T125E mutants showed
significant metastasis to both lungs and liver. However,
67NR cells transfected with wild-type TWIST1 and S127E
mutant did not show any metastasis to liver and very rare
metastasis to the lungs. As anticipated, 67NR cells alone
did not metastasize to either organ.

To explain our results, we determined the levels of
N-cadherin and vimentin, which are required for EMT
and metastasis in tumor samples of 4T1 and 67NR cells. As
shown in Figure 5, the expression levels of N-cadherin and
vimentin significantly diminished in 4T1 cells expressing
alanine mutants, and these results can explain as to why
4T1 cells expressing alanine mutants cannot metastasize.
However, S42E and T125E expressing 67NR cells did not
show a significant increase in N-cadherin and vimentin
expressions, although these cells showed significant
metastasis to lungs and liver.
Taken together, our results show that Akt-mediated
phosphorylation of TWIST1 can revert the nonmetastatic
phenotype of breast cancer cells into metastatic phenotype
and changes in expression of vimentin and N-cadherin
may not be enough to explain EMT. Since TWIST1
expression is limited to specific organs in adults, it is
conceivable that TWIST1 would be a cancer-preferential
drug target to prevent metastasis of breast cancer.
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Figure S1. Confirmation of mutations obtained by Site-Directed Mutagenesis with sanger sequence.
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